Clinical Trial: MLS101 Study in PMDD

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818720) titled 'MLS101 Study in PMDD' on Aug. 25.

Brief Summary: The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD). The main question it aims to answer is:

* Test the safety and tolerability of the study drug, MLS101 in premenopausal women (ages 18-50 inclusive) with PMDD.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Premenstrual Dysphoric Disorder ( PMDD) PMDD

Intervention: DRUG: MLS101 psilocybin

Patients will be randomized in a 1:1:1:1 ratio to receive 6 doses of either placebo or MLS101 at 2 mg, 4 mg, or 8 mg

DRUG: Plac...